Royal Bank Of Canada Reaffirms Sector perform Rating for Dr. Martens (LON:DOCS)

Dr. Martens (LON:DOCS)‘s stock had its “sector perform” rating restated by investment analysts at Royal Bank Of Canada in a research note issued to investors on Tuesday, Marketbeat.com reports.

Other equities analysts have also issued research reports about the stock. Berenberg Bank reaffirmed a “buy” rating on shares of Dr. Martens in a research report on Tuesday, January 27th. Peel Hunt restated a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of GBX 6,000.

Dr. Martens Price Performance

LON DOCS opened at GBX 66.85 on Tuesday. The stock has a 50-day simple moving average of GBX 75.22 and a 200 day simple moving average of GBX 82.85. Dr. Martens has a twelve month low of GBX 43.02 and a twelve month high of GBX 100.87. The stock has a market capitalization of £646.15 million, a PE ratio of 39.32, a P/E/G ratio of 6.40 and a beta of 0.11. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85.

Dr. Martens (LON:DOCS) last released its earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share (EPS) for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. Research analysts anticipate that Dr. Martens will post 2.5809394 EPS for the current year.

Insider Transactions at Dr. Martens

In other Dr. Martens news, insider Robert Hanson purchased 96,000 shares of the stock in a transaction on Friday, December 5th. The shares were purchased at an average price of GBX 79 per share, with a total value of £75,840. Over the last 90 days, insiders have acquired 97,130 shares of company stock valued at $7,673,816. Insiders own 2.79% of the company’s stock.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.